ACRP Certified Professional ACRP-CP Dumps Full Questions with Free PDF Questions to Pass
100% Updated ACRP ACRP-CP Enterprise PDF Dumps
NEW QUESTION # 54
The process of ensuring and documenting that an electronic data processing system conforms to the sponsor's established requirements for completeness, accuracy, reliability, and consistent intended performance is called:
- A. Programming
- B. Quality Assurance
- C. Validation
- D. Quality Control
Answer: C
Explanation:
Validation is the process of ensuring that an electronic data processing system meets the sponsor's specifications for completeness, accuracy, reliability, and consistent performance. It involves systematic testing and documentation to demonstrate that the system functions as intended, especially in the context of capturing, processing, and managing clinical trial data.
GCP guidelines specify that validation of electronic systems is crucial to maintain data integrity and compliance with regulatory standards.
"Validation ensures that electronic data systems function according to the sponsor's requirements, maintaining data accuracy and reliability." Objectives:
Maintain data integrity and reliability.
Demonstrate system compliance with regulatory requirements.
NEW QUESTION # 55
The sponsor should supply a PI with the IP after:
- A. Approval of protocol by the PI.
- B. Approval of protocol by the sponsor.
- C. Approval/favorable opinion from IRB/IEC and regulatory authority.
- D. Submission of documents to IRB/IEC and regulatory authority for review.
Answer: C
Explanation:
The sponsor may only provide the investigational product (IP) after the IRB/IEC and relevant regulatory authorities have approved the protocol. This ensures that the trial complies with ethical and legal standards before initiating IP administration.
According to GCP guidelines, sponsors must wait for all necessary approvals before distributing IP to the trial site.
"The investigational product may only be supplied after obtaining regulatory and IRB/IEC approval to ensure ethical conduct of the trial." Objectives:
* Ensure regulatory compliance before initiating IP distribution.
* Protect participant safety and ethical standards.
NEW QUESTION # 56
A protocol requires participants to take 1 tablet of IP per day. At each visit, participants are supplied with enough IP for 35 days. They are asked to return any unused IP at the next visit. One participant returns at the
1-month visit at 30 days with 10 tablets of unused IP and at the 2-month visit at 60 days with 12 tablets of unused IP. What is the participant's overall compliance?
- A. 77%
- B. 80%
- C. 71%
- D. 66%
Answer: A
Explanation:
Step 1:Calculate the total number of tablets dispensed:
* Month 1: 35 tablets
* Month 2: 35 tablets
* Total: 70 tablets
Step 2:Calculate the number of tablets returned:
* Month 1: 10 tablets
* Month 2: 12 tablets
* Total: 22 tablets
Step 3:Calculate the number of tablets taken:
* 70 - 22 = 48 tablets
Step 4:Calculate compliance:
* Compliance = (Tablets Taken / Total Tablets) × 100
* Compliance = (48 / 62) × 100 # 77%
GCP guidelines require accurate calculation of compliance based on returned IP counts, ensuring proper dose administration monitoring.
"Compliance rates are calculated by comparing the number of tablets taken to the total number of tablets dispensed, considering the returned count." Objectives:
* Monitor compliance with IP administration.
* Ensure accurate calculation of adherence rates.
NEW QUESTION # 57
A protocol inclusion criterion requires the serum magnesium at screening to be within the normal range. After the subject received IP, the CRC discovers the subject's screening magnesium level was below the normal range and the sub-investigator marked the lab sheet as not clinically significant. Which of the following should be done FIRST?
- A. Notify the regulatory authority.
- B. Notify the sponsor.
- C. Withdraw the subject.
- D. Notify the subject.
Answer: B
Explanation:
When a protocol deviation is identified, especially one involving inclusion criteria, the sponsor must be notified immediately. The sponsor will assess the deviation and determine whether the subject can continue in the study. Early notification ensures appropriate action and compliance with protocol and regulatory guidelines.
This answer aligns with GCP principles that mandate sponsor notification in case of protocol deviations, especially when they may impact participant safety or data integrity.
"Any deviation from the protocol that affects subject eligibility must be reported to the sponsor immediately for evaluation and guidance." Objectives:
* Maintain adherence to protocol inclusion criteria.
* Report deviations promptly for safety assessment.
NEW QUESTION # 58
Which of the following activities would be undertaken by the sponsor to BEST ensure overall quality of the study data?
- A. Ensure there is an accompanying written record that describes the consent process.
- B. Ensure submission of a data management plan to the regulatory authorities.
- C. Conduct annual reviews of the protocol and accompanying study documents.
- D. Develop a plan that describes the monitoring approach for a clinical study.
Answer: D
Explanation:
Developing a monitoring plan that outlines the approach to quality assurance is essential for maintaining data integrity throughout the clinical trial. This plan helps identify critical data points, risk-based monitoring strategies, and procedures for detecting and correcting data discrepancies. It ensures that the study data collected is accurate, complete, and verifiable.
GCP guidelines emphasize the importance of a monitoring plan to safeguard the quality and integrity of study data.
"The sponsor should develop a comprehensive monitoring plan to ensure the accuracy, completeness, and consistency of trial data." Objectives:
* Maintain high-quality data through structured monitoring.
* Identify potential risks and address them proactively.
NEW QUESTION # 59
The coding system for a double-blind clinical trial is accessible by the:
- A. IRB/IEC
- B. Sponsor
- C. Regulatory authority
- D. PI
Answer: B
Explanation:
The sponsor is typically responsible for maintaining the code that links the treatment assignment to participants in a double-blind clinical trial. The code is securely maintained and is only accessible in cases where unblinding is necessary for safety reasons. This process helps to preserve the integrity of the study while allowing for emergency unblinding if needed.
GCP guidelines state that the sponsor should maintain the blind unless unblinding is necessary due to safety concerns or regulatory requirements.
"The sponsor maintains the randomization code and ensures that unblinding occurs only when necessary, to protect the study's integrity." Objectives:
* Maintain the integrity of double-blind trials.
* Allow controlled access to randomization codes.
NEW QUESTION # 60
In an investigator-initiated study, who is responsible for implementing appropriate corrective and preventive actions when significant non-compliance is discovered?
- A. IRB/IEC
- B. PI
- C. CRC
- D. CRA
Answer: B
Explanation:
In investigator-initiated studies, the PI holds primary responsibility for addressing non-compliance, including root cause analysis and implementation of CAPA plans. This ensures that any issues affecting the study's integrity are adequately addressed and prevented in the future.
The answer is verified based on ICH E6(R2) guidelines which emphasize the PI's responsibility for maintaining compliance at the study site.
"The PI must develop and implement corrective and preventive actions when non-compliance is identified during the study." Objectives:
* Maintain compliance in investigator-initiated studies.
* Address non-compliance through CAPA.
NEW QUESTION # 61
Who ensures information regarding payments to subjects is documented in a written consent form?
- A. IRB/IEC
- B. Coordinator
- C. PI
- D. Sponsor
Answer: A
Explanation:
The IRB/IEC is responsible for reviewing and approving the consent form, which must include any information about payments to participants. This ensures transparency and ethical compliance regarding compensation.
The answer is verified according to GCP guidelines, which mandate IRB/IEC review of consentforms, including payment details.
"IRB/IEC must ensure that the informed consent process is thorough and includes disclosure of any compensation or payment to participants." Objectives:
* Guaranteeing informed consent quality
* Ensuring transparency about participant payments
NEW QUESTION # 62
An impartial witness should be present during the entire informed consent discussion when:
- A. A subject has been determined to be vulnerable.
- B. An interpreter is translating the consent form for a subject.
- C. A parent/guardian is consenting for a minor subject.
- D. A legally acceptable representative is unable to read.
Answer: D
Explanation:
An impartial witness is required when a legally acceptable representative (LAR) or the subject themselves cannot read. The witness ensures that the information is presented accurately and that the consent process is conducted ethically. The witness also signs the consent form to confirm that the subject or representative understands the study details.
GCP guidelines require an impartial witness to be present to confirm that the consent information is correctly conveyed and understood when the subject or LAR cannot read.
"An impartial witness is required when the subject or legally acceptable representative is unable to read, ensuring the consent process is transparent and ethically sound." Objectives:
* Protect the rights of individuals with literacy challenges.
* Maintain ethical standards in the consent process.
NEW QUESTION # 63
A study sponsor approaches a facility about participating in their research study. The study sponsor requires use of social media as its sole method of recruitment. The site knows their institutional IRB/IEC does not approve of social media recruiting. How should the site respond?
- A. Recruit for the study without use of social media.
- B. Rely on the sponsor to notify the IRB/IEC.
- C. Use a central IRB/IEC.
- D. Decline the study.
Answer: D
Explanation:
If the IRB/IEC has a policy that does not permit social media recruiting, the site must adhere to these regulations. Proceeding with a method not approved by the IRB/IEC would violate compliance requirements, so declining the study is the correct course of action.
The answer aligns with IRB/IEC regulations that prioritize ethical and compliant recruitment methods.
"Sites must follow the recruitment methods approved by their IRB/IEC to maintain compliance and ethical standards." Objectives:
* Adhering to ethical recruitment practices.
* Maintaining compliance with IRB/IEC policies.
NEW QUESTION # 64
During a mid-study sponsor audit of a clinical trial, the auditor notices that all of the protocol-required subject drug dosing diaries were incomplete. The effect of this will be the inability to:
- A. Evaluate study data.
- B. Verify compliance with IP regimen.
- C. Validate protocol endpoints.
- D. Conduct safety analysis.
Answer: B
Explanation:
Subject drug dosing diaries are essential for documenting adherence to the investigational product (IP) regimen. Incomplete or missing diaries compromise the ability to verify whether subjects followed the dosing schedule, which directly affects the trial's data integrity and the reliability of efficacy and safety assessments.
GCP guidelines stress the importance of maintaining accurate and complete dosing records to verify subject compliance with the protocol.
"Accurate documentation of dosing is essential to verify compliance with the investigational product regimen and ensure data accuracy." Objectives:
* Maintain accurate IP administration records.
* Ensure compliance monitoring throughout the study.
NEW QUESTION # 65
A Phase I drug trial has been completed and preparations are being made to proceed to a Phase II trial. Who is responsible for revising the IB with this updated information?
- A. Health authority
- B. Sponsor
- C. Investigator
- D. DSMB/IDMC
Answer: B
Explanation:
The sponsor is responsible for updating the Investigator's Brochure (IB) with new information obtained from the completed Phase I trial. The IB must reflect the most current data on the drug's safety, efficacy, and dosing to support Phase II planning and execution.
According to GCP guidelines, the sponsor must ensure that the IB is updated regularly with relevant findings from ongoing and completed trials.
"The sponsor is responsible for ensuring that the Investigator's Brochure is updated with the latest safety and efficacy data before advancing to the next phase of the trial." Objectives:
* Keep the IB current and accurate.
* Inform investigators of the latest safety and efficacy data.
NEW QUESTION # 66
A clinical trial where participants will be randomized to receive a sequence of two medications has which design configuration?
- A. Parallel Group
- B. Crossover
- C. Group sequential
- D. Factorial
Answer: B
Explanation:
A crossover study design involves participants receiving multiple interventions sequentially, with a washout period in between to minimize carryover effects. This design allows each participant to serve as their own control, increasing statistical power while reducing variability. It is commonly used when comparing two treatments or interventions.
GCP guidelines classify a crossover design as one where subjects receive multiple treatments in a specified sequence.
"In crossover trials, participants receive each intervention in a specific order, allowing for within-subject comparison." Objectives:
* Understand the structure of crossover studies.
* Improve statistical efficiency through self-control comparisons.
NEW QUESTION # 67
A trial subject was involved in a traffic accident. The emergency room (ER) doctor notifies the investigator that he wants to give the subject a blood transfusion. Blood transfusion is one of the prohibited treatments in the trial. How should the investigator respond?
- A. Report this incident immediately to the sponsor and leave the treatment decision to them.
- B. Ask the ER doctor not to transfuse blood and consider another treatment compliant with the protocol.
- C. Advise the ER doctor to transfuse blood, and the PI should withdraw the subject from the trial.
- D. Advise the ER doctor to transfuse the blood, and the PI should report this incident to the sponsor.
Answer: D
Explanation:
The investigator must prioritize the subject's immediate health and safety. In a medical emergency, the appropriate response is to advise the ER doctor to proceed with the necessary medical intervention (blood transfusion). Afterward, the PI must promptly report the incident to the sponsor as a protocol deviation.
GCP guidelines emphasize that patient safety takes precedence over protocol requirements in emergency situations.
"In situations where immediate medical intervention is necessary to prevent harm, the investigator should ensure that the appropriate care is given and subsequently report the event as a deviation." Objectives:
* Prioritize patient safety in emergencies.
* Report protocol deviations promptly.
NEW QUESTION # 68
Which of the following reports should be retained in participant charts?
- A. Safety reports
- B. DSMB/IDMC reports
- C. Lab reports
- D. IRB/IEC progress reports
Answer: C
Explanation:
Lab reports contain individual participant data relevant to their health status and the study's outcomes. These reports are essential for verifying subject safety and evaluating the effects of the investigational product (IP).
Therefore, they must be retained in the participant's medical records.
According to GCP guidelines, participant charts must include laboratory data as part of the essential documents to ensure accurate and complete clinical records.
"Lab reports must be maintained as part of the participant's chart for safety monitoring and data verification." Objectives:
* Maintain comprehensive medical records for each participant.
* Ensure availability of clinical data for audit and review.
NEW QUESTION # 69
All of the following are steps to assure an effective risk management approach while conducting a clinical study EXCEPT:
- A. Documenting all possible risk scenarios.
- B. Identifying potential study risks.
- C. Controlling risk by setting thresholds of risk acceptability.
- D. Assessing risk based on study impact.
Answer: A
Explanation:
While identifying potential risks, assessing them based on their impact, and setting risk acceptability thresholds are integral parts of a risk management approach, documenting every possible risk scenario is impractical and unnecessary. Instead, focus should be on identifying and managing the most significant and likely risks that could affect the study's quality and safety.
GCP guidelines emphasize identifying, assessing, and controlling critical risks rather than exhaustively documenting all hypothetical scenarios.
"Effective risk management involves identifying key risks, evaluating their impact, and setting control measures, rather than documenting every possible risk." Objectives:
* Implement practical and targeted risk management strategies.
* Focus on significant and likely risks rather than hypothetical ones.
NEW QUESTION # 70
A quality assurance audit of the EDC system SOP revealed a deficiency. Which of the following is the MOST likely reason?
- A. The number of users with access was not defined.
- B. The frequency of data backup was not defined.
- C. The list of comparable technology solutions was not included.
- D. The number of unique eCRF templates was not specified.
Answer: B
Explanation:
The frequency of data backup is a critical element of an Electronic Data Capture (EDC) system's Standard Operating Procedure (SOP). Ensuring regular and systematic data backup is essential for protecting trial data against loss or corruption. Failure to specify backup frequency indicates a gap in data security management.
GCP guidelines stress that data protection, including regular backups, is essential to maintaining data integrity in clinical trials.
"EDC system SOPs must include clear guidelines on data backup frequency to safeguard the integrity and availability of study data." Objectives:
* Ensure data security through regular backups.
* Maintain data integrity in clinical research.
NEW QUESTION # 71
The PI did not record the relationship to IP in the medical chart when assessing an adverse event. The CRC noticed the omission and brought it to the PI's attention. How should this be addressed?
- A. The CRC should amend the medical chart.
- B. The CRC should write a note to file.
- C. The PI should amend the medical chart.
- D. The PI should notify the monitor.
Answer: C
Explanation:
The PI is responsible for ensuring accurate documentation of adverse events (AEs) in the medical chart, including their relationship to the investigational product (IP). If an omission is identified, the PI must correct it by making a dated and signed amendment to maintain data accuracy and completeness.
GCP guidelines state that the PI must maintain accurate and complete records, including the assessment of the relationship between AEs and the IP.
"The investigator must document the assessment of the relationship between the AE and the investigational product to ensure accurate clinical records." Objectives:
* Maintain accuracy in adverse event documentation.
* Ensure data integrity through appropriate corrections.
NEW QUESTION # 72
......
Use Valid Exam ACRP-CP by ITCertMagic Books For Free Website: https://www.itcertmagic.com/ACRP/real-ACRP-CP-exam-prep-dumps.html
Free ACRP Certified Professional ACRP-CP Official Cert Guide PDF Download: https://drive.google.com/open?id=1INZDtHfYZB5JB3wRZIpPqhtxdRY3BMRf